About Steven Paul
Steven Paul is a director at Rapport Therapeutics.
Form D filings name Steven Paul as a director at Seaport Therapeutics.
Steven Paul reports to the SEC as a director or officer of 8 public companies, including Seaport Therapeutics (SPTX), Karuna Therapeutics (KRTX) and Sage Therapeutics (SAGE).
Steven Paul first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Steven Paul in the role, so the role may have started earlier or lasted longer.
RI
Rapport Therapeutics, Inc.
Director
2024 – 2026 · Public company (RAPP)
KI
Karuna Therapeutics, Inc.
CSO and President of R&D, director
2019 – 2024 · Public company (KRTX)
SI
Sage Therapeutics, Inc.
Director
2014 – 2024 · Public company (SAGE)
AI
Alnylam Pharmaceuticals, Inc.
Director
2010 – 2022 · Public company (ALNY)
VI
Voyager Therapeutics, Inc.
Chief Executive Officer and director
2015 – 2021 · Public company (VYGR)
SC
Sigma Aldrich Corp.
Director
2006 – 2015 · Public company (SIAL)
EC
Eli Lilly & Co.
EVP, Science and Technology
2006 – 2010 · Public company (LLY)
Key Colleagues at Startups
The people Steven Paul works with at each company, as listed on that company's latest Form D.
Seaport Therapeutics, Inc. · Form D, Oct 31, 2024
JH
James Healy
Director
MC
Michael Chen
Executive officer
LG
Lana Gladstein
General Counsel
DZ
Daphne Zohar
Executive officer and director
AL
Antony Loebel
Executive officer
DW
David Wheadon
Director
EG
Eric Green
Executive officer
RN
Robert Nelsen
Director
BC
Bharatt Chowrira
Director
DT
Denice Torres
Director
EE
Eric Elenko
Director
JP
Jason Pitts
Director